Kyverna Therapeutics (KYTX) Depreciation & Amortization (CF) (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Depreciation & Amortization (CF) data on file, last reported at $351000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 29.94% year-over-year to $351000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 23.37% YoY) and the FY2025 annual result came in at $1.8 million, down 15.66% from the prior year.
• Depreciation & Amortization (CF) slipped to $351000.0 in Q1 2026, from $368000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $563000.0 in Q4 2024 to a low of $351000.0 in Q1 2026.
• A 4-year average of $460769.2 and a median of $462000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) rose 28.33% — and 2025, when it sank 34.64%.
• Tracing KYTX's Depreciation & Amortization (CF) over 4 years: stood at $462000.0 in 2023, then climbed by 21.86% to $563000.0 in 2024, then slumped by 34.64% to $368000.0 in 2025, then decreased by 4.62% to $351000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $351000.0 (Q1 2026), $368000.0 (Q4 2025), and $415000.0 (Q3 2025), per Business Quant data.